---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-035908"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:29:32.396285+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics reports 2023 net loss $104.7M; cash $201.4M to fund to end 2025

## Summary
- Cash, equivalents & marketable securities $201.4M as of Dec 31, 2023; expected to fund operations through end of 2025.
- Net loss for FY 2023 was $104.7M ($2.38 per share) vs $101.1M ($2.60 per share) in 2022.
- Revenue from Acadia collaboration fell to $8.8M from $12.4M YoY.
- R&D expenses $82.2M (2022: $77.8M); G&A $41.3M (2022: $38.9M), driven by STK-001 and STK-002 development.
- Q4 2023 net loss $27.0M ($0.60 per share) vs $25.7M ($0.65 per share) in Q4 2022.

## SEC filing metadata
- accession: 0000950170-24-035908
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000095017024035908/0000950170-24-035908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000095017024035908/stok-20240325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-035908
- JSON: https://secwatch.observer/filing/0000950170-24-035908.json
- Plain text: https://secwatch.observer/filing/0000950170-24-035908.txt

## Key facts
- Earnings Releases
  Stoke Therapeutics, Inc. reported the full year ended December 31, 2023 results: revenue $8.8 million, net income $104.7 million, or $2.38 per share, EPS $2.38 per share.
  - Period: the full year ended December 31, 2023
  - Revenue: $8.8 million
  - Net income: $104.7 million, or $2.38 per share
  - EPS: $2.38 per share
  - Result: reported results
  source text: Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the year ended December 31, 2023 was $8.8 million, compared to $12.4 million, for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000095017024035908/0000950170-24-035908-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.